Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

MRI and MRS Diagnosis and Treatment Monitoring of Alzheimer's Disease With Novel Therapy

Authors not listed

Huntington Medical Research Institutes · 2011

Abstract

Cognitively normal individuals, patients with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) will undergo clinical screening, neuropsychological tests, blood and urine analyses, quantitative magnetic resonance imaging (MRI) and proton (1H ) and carbon 13 (13C) magnetic resonance spectroscopy (MRS). Each individual will receive minocycline oral administration for 4 weeks initially, after which MRI, MRS and neuropsychological results will be recorded. If no adverse side effects occur, subjects will continue minocycline administration for an additional 5 months.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Anonymous. (2011). MRI and MRS Diagnosis and Treatment Monitoring of Alzheimer's Disease With Novel Therapy. <em>Huntington Medical Research Institutes</em>. https://clinicaltrials.gov/study/NCT01463384
Vancouver
Anonymous. MRI and MRS Diagnosis and Treatment Monitoring of Alzheimer's Disease With Novel Therapy. Huntington Medical Research Institutes. 2011.
BibTeX
@misc{anon2011MRIand, title = {MRI and MRS Diagnosis and Treatment Monitoring of Alzheimer's Disease With Novel Therapy}, author = {Anonymous}, journal = {Huntington Medical Research Institutes}, year = {2011}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings